We are committed to serving the best interests of our shareholders.

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary TESARO Joins OCRFA as Presenting Sponsor of the 2017 Ovarian Cancer National Conference
WALTHAM, Mass., June 29, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Ovarian Cancer Research Fund Alliance (OCRFA) as the Presenting Sponsor of the 2017 Ovarian Cancer National Conference, being held July 7-9 in
View HTML
Toggle Summary TESARO Announces Lonnie Moulder and Mary Lynne Hedley Named EY Entrepreneurs of the Year® New England
WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to announce Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO, have been named EY Entrepreneurs of the Year ® in Life Sciences Development
View HTML
Toggle Summary TESARO Joins Healthcare Businesswomen's Association as Corporate Partner
WALTHAM, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, is proud to support the Healthcare Businesswomen's Association (HBA) as a Corporate Partner. HBA is the leading global organization committed to furthering the advancement
View HTML
Toggle Summary TESARO Announces Participation at Goldman Sachs 38th Annual Global Healthcare Conference
WALTHAM, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced its participation at the Goldman Sachs 38th Annual Global Healthcare Conference, to be held June 13-15, 2017 at the Terranea Resort in Rancho Palos
View HTML
Toggle Summary TESARO Provides Business and Pipeline Update at ASCO Investor Briefing
Initial TOPACIO data for niraparib plus KEYTRUDA ® is indicative of potentially synergistic anti-tumor activity in platinum-resistant ovarian cancer Phase 1 results for TSR-042 show anti-PD-1 activity Three posters presented during ASCO describe additional analyses of NOVA data Robust demand
View HTML
Toggle Summary TESARO Announces Presentations of Abstracts at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
Investor briefing to be webcast from Chicago on June 3, 2017 at 6:15 PM CT WALTHAM, Mass., May 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three ZEJULA™ (niraparib) abstracts at the 2017 American
View HTML
Toggle Summary National Survey Shows Resource, Emotional and Support Needs of the Ovarian Cancer Community
Launch of "Our Way Forward" Program Provides Resources to Support Women Bravely Facing Ovarian Cancer
View HTML
Toggle Summary TESARO Partners With Clinigen to Initiate European Managed Access Program for Niraparib in Patients With Recurrent Ovarian Cancer
WALTHAM, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- TESARO Inc. (NASDAQ:TSRO) and Clinigen Group plc's (AIM:CLIN) ('Clinigen') Idis Managed Access division have partnered to launch a Managed Access Program (also known as an Early Access Program) in Europe for the investigational PARP 1/2 inhibitor,
View HTML
Toggle Summary TESARO Announces First-Quarter 2017 Operating Results
ZEJULA™ approved by U.S. FDA for the maintenance treatment of women with recurrent ovarian cancer, regardless of BRCA or biomarker status; commercial launch underway ZEJULA added to the NCCN Clinical Practice Guidelines in Oncology Expanded development program for niraparib in ovarian, lung
View HTML
Toggle Summary TESARO Announces Submission of Investigational New Drug Application for Anti-LAG Antibody TSR-033 to the U.S. FDA
Phase 1 trial of TSR-033 planned to begin in mid-2017
View HTML